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ABSTRACT 
Background: We investigated the risk of chronic liver disease (CLD) due to alcohol 
consumption and body mass index (BMI) and the effects of their interaction in a 
prospective cohort study of women recruited to the UKCTOCS trial.  
Methods: 95,126 post-menopausal women without documented CLD were stratified into 
12 groups defined by combinations of BMI (normal, overweight, obese) and alcohol 
consumption (none, <1-15, 16-20 and ≥21 units/week), and followed for an average of 5.1 
years. Hazard ratios (HR) were calculated for incident liver-related events (LRE). 
Results: First LREs were reported in 325 (0.34%) participants. Compared to women with 
normal BMI, HR=1.44 (95% CI; 1.10-1.87) in the overweight group and HR=2.25 (95% CI; 
1.70-2.97) in the obese group, adjusted for alcohol and potential confounders. Compared 
to those abstinent from alcohol, HR=0.70 (95% CI; 0.55-0.88) for <1-15 units/week, 0.93 
(95% CI; 0.50-1.73) for 16-20 units/week and 1.82 (95% CI; 0.97-3.39) for ≥21 units/week 
adjusted for BMI and potential confounders. Compared to women with normal BMI drinking 
no alcohol, HR for LRE in obese women consuming ≥21 units/week was 2.86 (95% CI; 
0.67-12.42), 1.58 (95% CI; 0.96-2.61) for obese women drinking <1-15 units/week and 
1.93 (95% CI; 0.66-5.62) in those with normal BMI consuming ≥21 units/week after 
adjustment for potential confounders. We found no significant interaction between BMI and 
alcohol. 
Conclusion: High BMI and alcohol consumption and abstinence are risk factors for CLD 
in post-menopausal women. However, BMI and alcohol do not demonstrate significant 
interaction in this group. 
Trial Registration: UKCTOCS is registered as an International Standard Randomised 
Controlled Trial, number ISRCTN22488978. Registered 06/04/2000. 
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BACKGROUND 
Chronic liver disease (CLD) is the 5th commonest cause of death in the UK, and the only 
rising major cause of mortality and morbidity. 60,000 people in England and Wales have 
cirrhosis [1-3]. Recent data estimates that over 600,000 adults in the USA have CLD, with 
over half of affected individuals unaware of the diagnosis [4]. Overweight and alcohol 
consumption are major causes of CLD [5-7]. Non-alcoholic fatty liver disease (NAFLD) can 
be considered the pathological manifestation in the liver of the metabolic syndrome, of 
which high BMI is a key feature. [8]	   NAFLD comprises a spectrum of disease, from 
steatosis, through inflammation (steatoheaptitis) to fibrosis and cirrhosis. The precise 
influence of body mass index (BMI) on the risk of liver disease in women, however, is not 
conclusive and previous studies using smaller subsets of ICD-10 codes to identify liver-
related morbidity and mortality may have underestimated the impact of BMI and alcohol [9, 
10]. Further, interaction between alcohol and BMI and risk of liver disease is not well 
understood. Regardless of the etiology of liver disease, the clinicopathological outcome in 
those who develop CLD is cirrhosis [11] and the there may be common pathways in which 
alcohol and high BMI damage the liver [12]. A synergistic interaction between steatosis 
and alcohol consumption in the progression of fibrosis in patients with chronic hepatitis C 
has been demonstrated in histological studies [13]. 
Both alcohol consumption and NAFLD are common. Moderate alcohol consumption is 
associated with decreased mortality, largely due to reduced cardiovascular-related disease, 
but there are no guidelines related to alcohol use in NAFLD and these factors, in addition 
to rising levels of liver disease and the high prevalence of excess alcohol consumption, 
coupled with the worldwide increase in obesity demonstrate the need to further understand 
the roles of alcohol and BMI and their interaction in CLD. 
In a large cohort of women we investigated incidence of CLD and its relationship to alcohol 
and BMI, and examined the interaction between these two risk factors. 
 
METHODS  
Study population 
This prospective cohort study was nested in the United Kingdom Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS) [14]. UKCTOCS is a multi-center UK-based 
randomised controlled trial designed to define the effect of ovarian cancer screening on 
mortality. Between April 2001 and October 2005, 202,638 post-menopausal women aged 
50-74 were recruited in England, Wales and Northern Ireland. Participants were invited at 
random from 27 local authority registers. Exclusion criteria included bilateral oophorectomy, 
increased risk of familial ovarian cancer, previous ovarian cancer and active non-ovarian 
cancer. The trial design and detailed eligibility criteria have been described elsewhere [14-
16]. This study is nested within UKCTOCS, comprising of participants in England.	  
UKCTOCS was approved by the UK North West Multicentre Research Ethics Committee 
(North West MREC 00/8/34), with site-specific approval from the local regional ethics 
committees and the Caldicott guardians (data controllers) of the participating primary care 
trusts. Written informed consent was obtained from all volunteers. 
Exposures 
The exposures of interest were BMI and current weekly alcohol consumption. Participants 
completed a questionnaire at recruitment, which included self-reported height and weight. 
BMI was calculated (BMI (kg/m2) = weight (kg)/(height (m))2) and categorised according to 
the World Health Organisation’s definitions; normal (<25 kg/m2), overweight (25-<30 
kg/m2) or obese (≥30 kg/m2). As there are no existing population estimates for the range of 
BMI a pragmatic approach was adopted to selecting patients with plausible BMI values. 
Participants who recorded a height outside the range 140-210cm, or a weight outside the 
range 25-200kg, or where the BMI was outside the range 16-65 kg/m2 were excluded. 
Via a follow-up questionnaire 3-5 years after randomisation, participants estimated their 
current alcohol consumption as the number of drinks consumed per week (none, less than 
1, 1-3, 4-6, 7-10, 11-15, 16-20 or ≥21 drinks), assuming one drink is a glass of wine, half a 
pint of beer or cider, or a measure of spirits. Alcohol units were calculated using the 
convention that one drink is the equivalent of 1 UK unit (10ml or 8g of pure alcohol) [17]. 
Participants were categorised in the following groups; none, <1-15, 16-20 and ≥21 
units/week, and those with no alcohol response were excluded. 
Covariates 
The follow-up questionnaire asked participants to report known comorbidities including 
heart disease, hypercholesterolaemia, hypertension and diabetes mellitus, and whether 
they currently smoked (all categorised as yes/no). Socioeconomic status was estimated 
using the Index of Multiple Deprivation 2007 (IMD) (continuous variable) [18]. This 
ascribes a deprivation score to participants based on their postcode, with a higher score 
indicating higher deprivation. 
Follow up 
All participants are followed through a ‘flagging’ study with the NHS Information Centre for 
Health and Social Care in England and Wales which provided data on cancer registrations 
and deaths, with diagnosis/cause of death coded according to the International 
Classification of Diseases, version 10 (ICD-10). 99.98% of UKCTOCS participants were 
successfully flagged. In addition, hospital inpatient and outpatient episode data for 2001-
10 were available through linkage to the Hospital Episodes Statistics (HES) database. 
Each HES record reports a main diagnosis and up to 19 (inpatient admissions) and 11 
(outpatient appointments) further diagnoses and each death record reports the primary 
death code and additional diagnoses recorded on the death certificate. As HES data were 
only available for participants in England, only participants in England were included in this 
study. Women were included in the study from the point of return of questionnaire. Women 
with known pre-existing liver disease were not included, by excluding those where a code 
of interest had been registered between recruitment to UKCTOCS and return of 
questionnaire. 
Outcome 
The main outcome measure was first liver-related event (LRE), defined as first 
presentation of either a hospital admission, outpatient appointment, cancer registration 
with, or death from, an ICD-10 code of interest. The following codes for liver disease were 
searched for: K70 (alcoholic liver disease), K73 (chronic hepatitis) and K74 (fibrosis and 
cirrhosis). These codes are consistent with other UK studies of cirrhosis [1, 9]. We also 
included K76 (other diseases of liver, including fat) in order to widen the search for liver 
disease beyond cirrhosis to include fatty liver disease. In addition, codes relating to 
sequelae of decompensated liver disease were also searched for; I85 (oesophageal 
varices), Z94.4 (liver transplant) and C22.0 (hepatocellular carcinoma). In addition to ICD-
10 codes, death certificates were also searched for any mention of alcoholic liver disease 
or non-alcoholic fatty liver disease. 
 
Statistical analysis 
Crude incidence rates of first LRE were calculated using person-years of follow-up as the 
denominators, for each BMI group, each alcohol group and each BMI/alcohol combination. 
For each participant, person-years of follow-up were accrued from date that the follow-up 
questionnaire was returned (as this was the date that current alcohol use was ascertained), 
to the censorship date (February 1, 2013), date of first presentation with LRE, or death 
from any other cause. Participants who experienced a LRE at any time from randomisation 
to return of questionnaire were excluded. 
Separate influences of BMI and of alcohol on incident liver disease 
Cox proportional hazards models were used to calculate hazard ratios (HRs) of first LRE in 
three categories of BMI using normal BMI as the reference. Similar analysis was 
performed for alcohol with no alcohol consumption as the reference. The proportional 
hazards models were adjusted for BMI, or alcohol respectively.  
All potential confounding risk factors (smoking, IMD, hypertension, heart disease, 
hypercholesterolaemia, diabetes) were included individually in a Cox model to calculate 
univariate HRs for LREs, to guide their utility in the models evaluating risk due to BMI and 
alcohol. 
Influences of combinations of BMI and alcohol 
HRs were calculated for twelve BMI and alcohol combinations using the normal BMI / no 
alcohol consumption category as the reference, adjusted for potential confounders with 
significant HRs for LRE, and then adjusted only for factors associated with the metabolic 
syndrome (hypertension, hypercholesterolemia, heart disease and diabetes). The 
proportional hazards assumption was checked by examining the log minus log plot. 
Interaction between alcohol and BMI 
Interaction between alcohol using several thresholds and BMI (as a continuous variable) 
was analysed by calculating the interaction term from the Cox regression models. 
All analyses were performed using SPSS (version 19, SPSS Inc, Chicago, IL, USA) and 
STATA statistical software (StataCorp 2007. Release 10. College Station, TX, USA: 
StataCorp LP). 
 
RESULTS 
Of the 157,996 UKCTOCS participants resident in England, 62,870 were excluded 
including 321 women who experienced an LRE or died between recruitment and return of 
questionnaire and 14,295 (9%) with no data on smoking. The final cohort comprised 
95,126 participants (Figure 1). 
Baseline characteristics are shown in Table 1. 97.1% of the participants were white. 36% 
were smokers. 55% were either overweight (37%) or obese (19%). 23.4% reported 
drinking no alcohol and 1.5% reported drinking more than 21 units/week. Increasing BMI 
correlated with increased reporting of hypertension, heart disease, hypercholesterolaemia 
and diabetes. 
325 (0.34%) women experienced a first LRE over a total of 509,561 person-years of 
follow-up (mean 5.1 years), equivalent to 0.64 first events per 1000 person-years (3.3 per 
1000 women over 5 years). The most common ICD-10 code signaling a first presentation 
of LRE was K76 (table S1). Only 763 (0.8%) of participants were underweight (BMI <18·5 
kg/m2) and in this group there were only 4 LREs, therefore this group was combined with 
the normal BMI group. 1,237 (7% of the obese group) women could be classified as 
morbidly obese (BMI ≥ 40 kgm-2) and in this group, the event rate was highest (1.98 
events per 1000 person years (95% CI; 1.05-3.38)). There were 2713 (2.9%) deaths from 
any cause. 
Table 1. Baseline characteristics, number of first events according to BMI category and in 
all participants and hazard ratios for LRE for potential confounders (continuous* and 
categorical** variables) 
BMI, body mass index; IMD, Index of Multiple Deprivation; LRE, liver-related event. 
 
 
 
 
Characteristic BMI category (kg/m2) All 
participants 
Hazard 
ratio (95% 
confidence 
intervals) 
<25 25 - <30 ≥30 
Total, n (%) 42,452 
(44.6) 
35,073 
(36.9) 
17,601 
(18.5) 
95,126  
Recruitment age, 
median (years) 
60.0 
(50-74) 
61.0 
(50-74) 
60.0 
(50-74) 
60.0 
(50-74) 
1.01* 
(0.99-1.02) 
Smoker, n (%) 14,740 
(34.7) 
12,616 
(36.0) 
6621 
(37.6) 
33,977 
(35.7) 
1.89** 
(1.52-2.35) 
Hypertension, n (%) 9477 
(22.3) 
12,116 
(34.5) 
8440 
(48.0) 
30,033 
(31.6) 
1.38** 
(1.11-1.73) 
Heart disease, n (%) 1721 
(4.1) 
2086 
(5.9) 
1416 
(8.0) 
5223 
(5.5) 
2.17** 
(1.53-3.06) 
Hypercholesterolemia, n 
(%) 
8001 
(18.8) 
9148 
(26.1) 
5440 
(30.9) 
22,589 
(23.7) 
1.68** 
(1.33-2.11) 
Diabetes, n (%) 836 
(2.0) 
1689 
(2.6) 
2263 
(12.9) 
4788 
(5.0) 
2.76** 
(1.99-3.83) 
IMD, mean 17.0 18.7 21.3 18.5 1.09* 
(1.01-1.03) 
Alcohol consumption 
(units/week) 
     
None 8479 
(20.0) 
8189 
(23.3) 
5547 
(31.5) 
22,215 
(23.4) 
1** 
(reference) 
<1-15 31,811 
(74.9) 
25,324 
(72.2) 
11,473 
(65.2) 
68,608 
(72.1) 
0.64** 
(0.51-0.82) 
16-20 1448 
(3.4) 
1067 
(3.0) 
366 
(2.1) 
2881 
(3.0) 
0.82** 
(0.44-1.53) 
≥21 714 
(1.7) 
493 
(1.4) 
215 
(1.2) 
1422 
(1.5) 
1.66** 
(0.89-3.09) 
Alcohol consumption 
(units/week) 
Number of first LREs  
None 23 36 42 101  
<1-15 71 77 55 202  
16-20 17 10 3 11  
≥21 4 5 2 11  
Total 102 123 100 325  
Risk of liver-related events due to potential confounders 
Other covariates also demonstrated independent association with liver-related events 
(Table 1). Significant HRs were seen with smoking, hypertension, heart disease, 
hypercholesterolaemia, diabetes and IMD. 
BMI and risk of liver-related events 
Crude rates of LREs increased with rising BMI. HRs for LRE were significantly higher in 
both overweight (1.44, 95% CI; 1.10-1.87) and obese categories (2.25, 95% CI; 1.70-2.97) 
compared to the normal BMI group. A fully adjusted model is presented incorporating 
adjustment for confounders with significant HRs (Table 2). 
Alcohol consumption and risk of liver-related events 
The rate of LRE was lowest in the group drinking <1-15 units weekly and increased with 
abstinence and increasing alcohol use. This tendency towards a “J-shaped” relationship 
between LRE and alcohol consumption was preserved after adjustment for BMI, with 
lowest HRs in the <1-15 units/week group, although the there was no statistically 
significant difference between the HRs for this group and the reference group. A fully 
adjusted model is shown, adjusted for variables with significant HRs for LRE (Table 2). 
In the group reporting no alcohol consumption the proportion of LREs that were alcohol-
related was 3.96% compared to 11.16% in those drinking any alcohol. 
 
 
 
 
Table 2. Event rates and adjusted hazard ratios of first liver-related events, according to 
BMI category and according to alcohol category 
 
BMI and alcohol 
categories 
First event rate per 
1000 person years 
(95% confidence 
intervals) 
Hazard ratio (95% 
confidence intervals)* 
Hazard ratio (95% 
confidence 
intervals)** 
BMI category (kg/m2)    
<25 0.45 
(0.4-0.5) 
1 
(reference) 
1 
(reference) 
25 - <30 0.65 
(0.5-0.8) 
1.44 
(1.10-1.87) 
1.31 
(1.01-1.72) 
≥30 1.06 
(0.9-1.3) 
2.25 
(1.70-2.97) 
1.85 
(1.38-2.48) 
Alcohol category (units/week)  
None 0.86 
(0.7-1.0) 
1 
(reference) 
1 
(reference) 
<1-15 0.55 
(0.5-0.6) 
0.70 
(0.55-0.88) 
0.78 
(0.61-1.00) 
16-20 0.68 
(0.3-1.2) 
0.93 
(0.50-1.73) 
0.97 
(0.52-1.82) 
≥21 1.37 
(0.7-2.5) 
1.82 
(0.97-3.39) 
1.83 
(0.97-3.44) 
* Adjusted for BMI (continuous variable) or alcohol category as appropriate. 
** Adjusted for BMI (continuous variable) or alcohol category as appropriate and smoking, 
hypertension, heart disease, hypercholesterolaemia, diabetes and IMD. 
 
Risk of liver-related events in participants grouped in to combinations of BMI and 
alcohol use 
Participants were grouped according to combinations of BMI and alcohol consumption. 
Table 3 shows the rates of LRE in each group. The fully adjusted Cox model shows that 
the lowest risk is in those with normal BMI consuming <1-15 units/week. Within the normal 
BMI group, abstinence or drinking >16 units/week increases the risk of LRE, although 
there are wide confidence intervals. 
Among overweight and obese women, the nadirs of risk were in the <1-15 units/week 
groups, and as in the normal BMI group, the risk was highest in the highest alcohol group 
(HR 3.32, 95% CI; 1.25-8.81; and HR 2.86, 95% CI; 0.67-12.21 respectively). 
To estimate the effect of cardiovascular disease and diabetes on the morbidity associated 
with fatty liver disease, HRs were adjusted for confounding factors associated with the 
metabolic syndrome. When elements of the metabolic syndrome were controlled for, risk 
of LRE attributable to heavier drinking increased. This suggests that the risk of liver 
disease attributable to BMI in patients with, or at risk of, metabolic syndrome is not entirely 
accounted for by hypertension, heart disease, hypercholesterolemia or diabetes, but may 
be partly attributable to steatosis itself. 
When separated by BMI group, the trend to a “J-shaped” relationship of risk of LRE 
remains in all BMI groups, with risk highest in the abstainers and heavier drinkers, 
compared to those in the <1-15 units/week alcohol groups. 
Table 3. Event rates and hazard ratios of first liver-related event according to various BMI 
and alcohol combinations 
BMI category 
(kg/m2) 
Alcohol category (units/week) 
None <1 – 15 16 – 20 ≥21 
 First event rate per 1000 person years (95% confidence intervals) 
<25 0.52 
(0.3-0.8) 
0.42 
(0.3-0.5) 
0.50 
(0.1-1.3) 
1.00 
(0.3-2.6) 
25 - <30 0.83 
(0.6-1.2) 
0.57 
(0.4-0.7) 
0.84 
(0.3-2.0) 
1.81 
(0.6-4.2) 
≥30 1.43 
(1.0-1.9) 
0.88 
(0.7-1.1) 
0.98 
(0.1-3.5) 
1.68 
(0.2-6.1) 
 Hazard ratio (95% confidence intervals) 
adjusted for smoking, hypertension, heart disease, 
hypercholesterolaemia, diabetes and IMD. 
<25 1 
(reference) 
0.91 
(0.56-1.47) 
1.03 
(0.35-2.99) 
1.93 
(0.66-5.62) 
25 - <30 1.46 
(0.85-2.50) 
1.34 
(0.71-1.83) 
1.61 
(0.61-4.26) 
3.32 
(1.25-8.81) 
≥30 2.28 
(1.35-3.86) 
1.58 
(0.96-2.61) 
1.67 
(0.39-7.15) 
2.86 
(0.67-12.21) 
 Hazard ratio (95% confidence intervals) 
adjusted for hypertension, heart disease, hypercholesterolemia 
and diabetes 
<25 1 
(reference) 
0.85 
(0.53-1.37) 
1.07 
(0.37-3.09) 
2.13 
(0.74-6.17) 
25 - <30 1.51 
(0.89-2.55) 
1.11 
(0.69-1.76) 
1.74 
(0.66-4.57) 
3.69 
(1.40-9.72) 
≥30 2.35 
(1.40-3.95) 
1.59 
(0.97-2.60) 
1.89 
(0.44-8.01) 
3.16 
(0.74-13.41) 
 
 
 
 
Interaction between alcohol and BMI 
Interaction terms were calculated for BMI (continuous) and alcohol, using thresholds for 
high alcohol of ≥16 units/week and ≥21 units/week. There was no significant interaction 
between BMI and high alcohol use. Similarly, no interaction was seen with BMI and any 
alcohol use. 
 
DISCUSSION 
Main findings 
The most striking finding of this study is the risk of liver disease associated with 
overweight/obesity in post-menopausal women. While the association between alcohol 
consumption and CLD is well established, there is still much to characterise in the natural 
history of non-alcoholic fatty liver disease (NAFLD) [3]. Furthermore the study supports the 
adverse impact of heavy drinking compounding the effects of overweight and obesity. 
Strategies for preventing and detecting liver disease should be developed accommodating 
these findings.  
This study suggests that in women aged 50-74, those consuming <1-15 units/week are at 
lowest risk of liver disease. Those drinking 16-20 units/week are only marginally more at 
risk. The UK Institute of Alcohol Studies defines hazardous drinking as more than 14 
units/week and harmful drinking as >35 units/week which would be consistent with the 
observations in our study population.  
Those that are overweight or obese have an increased risk of liver disease. Women of 
normal BMI who drink <1-15 units/week are at lowest risk, compared to those who drink 
more or who abstain. It is possible, however, that some abstainers had previously been 
heavy drinkers. This is supported by our data showing that 4% of LREs in the abstainers 
were alcohol related. 
When combinations of risk are considered, compared to a baseline of normal BMI and 
abstinence, higher BMI (≥30 kg/m2) confers a greater risk than higher alcohol consumption 
(≥21 units/week). The highest risk is in those who are overweight or obese and drink the 
most alcohol. 
After adjustment for confounding due to metabolic risk factors, HRs in the two highest 
alcohol categories increased in all BMI groups, suggesting that these factors may 
contribute to the risk of CLD. It is biologically plausible that diabetes, 
hypercholesterolaemia and hypertension may contribute to liver disease over and above 
that caused by fatty liver disease and alcoholic liver toxicity. The corollary is that obesity 
can cause liver morbidity and mortality in the absence of the metabolic syndrome, 
providing evidence that case ascertainment cannot be restricted to overweight or obese 
patients with features of the metabolic syndrome and challenging the “two hit” and “three 
hit” hypotheses [19].  
Strengths and limitations 
Strengths of this study include the size and duration of follow-up, the prospective design 
and the independence of the data capture for outcomes. This study was also able to adjust 
for confounding factors, which has not been possible in other cross-sectional studies. In an 
effort to capture all morbidity and mortality attributable to liver disease, rather than just 
cirrhosis, we selected ICD-10 codes that encompass a clinically relevant group of diseases 
including codes for CLD and those relating to the consequences of decompensated liver 
disease. This was designed to maximise the ability to detect liver disease.  
Limitations include reliance on self-reporting of alcohol consumption, co-morbidities, height 
and weight, which may be a factor in the wide confidence intervals seen for all HR 
estimates. However, good reliability of self-reporting height and weight [20-24], and alcohol 
[25-27], has been demonstrated in other studies. 
Height and weight were reported at recruitment, and alcohol consumption reported, later, 
on the follow-up questionnaire. Participants were asked to report current alcohol use, 
rather than lifetime patterns. Changes in drinking patterns would not have been identified, 
and this method of data collection may fail to identify episodic (“binge”) drinkers. We used 
the convention that one drink is equivalent to 1 unit of alcohol. However assumptions 
about alcohol content are difficult to make as measures of volume are likely to vary 
depending on where the alcohol is consumed, and the alcohol content of drinks continues 
to change. There is evidence that the number of units in alcoholic drinks in the UK have 
been undercounted [28], however we have used the standard 1 drink = 1 unit as this 
remains a widely used convention, particularly in public health promotion.  
Reliance on ICD-10 to define events may result in errors due to mis-coding. We used 
additional codes to those used to define cirrhosis in order to maximize the capture of 
cases, but these may also be subject to mis-coding. We attempted to reduce the risk of 
non-coding of events by using 3 independent sources, and in the case of death 
certification also used hand searching of key words in the text of death certificates. Also, 
the HES database may not capture some areas of healthcare, for example the private 
sector. The number of LREs that included ICD-10 Z94.4 is surprising (Table S1). This may 
be because participants with liver transplants are engaged in hospital care and are easily 
identified and coded.  
Only post-menopausal women aged 50-74 were included with 97% being white. The loss 
to follow up rate in UKCTOCS was very small (0.02%). The acceptance rate was 23%. 
However, despite attempts to ensure that UKCTOCS was representative of the general 
population [15] there was a ‘healthy volunteer effect’ [29] on both overall and cause-
specific mortality, which may have an effect on the generalisability of findings [18]. 
Although the health section of the follow-up questionnaire did not specifically ask about 
liver disease, we excluded those who had a code of interest recorded between recruitment 
to UKCTOCS and the start of this study. However, exclusion of all participants with known 
CLD could not be guaranteed.  
It is unlikely that viral hepatitis made a significant contribution to LRE based on low 
prevalence in the demographic of women in this study [30]. During the follow-up period in 
our study, only 21 (0.02%) of participants had a code for viral hepatitis recorded. 
Other studies 
A number of studies have demonstrated a reduced risk of liver disease in patients with 
NAFLD who consume low or moderate amounts of alcohol [31-33], and it has been 
suggested that these levels of alcohol use may be associated with beneficial effects of 
insulin sensitivity in post-menopausal women [34]. However, at higher extremes of BMI 
and alcohol use, data is not conclusive. Previous studies have attributed a lower incidence 
of CLD to BMI and alcohol, and as expected a lower incidence of CLD when only alcoholic 
cirrhosis is examined [35]. However these have relied on cirrhosis codes alone, ignoring 
complications characterising decompensated cirrhosis that are indicative of CLD and 
clearly associated with BMI and alcohol included in the present study. This study is in 
broad agreement with some other studies including the National Health and Nutrition 
Examination Survey (NHANES) [6] which found increasing risk with both increasing BMI 
and alcohol, but no excess risk in overweight or obese drinkers or in abstainers. A Scottish 
prospective study reported increasing risk with increasing BMI in men, but not in women 
[10]. A sub-analysis of men found the lowest risk of CLD in abstainers with normal BMI 
with a supra-additive interaction between BMI and alcohol [36]. The UK-based Million 
Women Study [9] used a limited range of ICD-10 codes to identify cirrhosis and reported a 
rate of hospital admission or death from liver disease less than half that found in our study. 
However, as in our study, highest risk was in overweight or obese women consuming the 
most alcohol. In a study of patients with a history of alcohol excess who were admitted to 
hospital with an alcohol-related problem, risk of cirrhosis was twice as high among the 
overweight group as those with normal BMI [37]. A recent prospective study of 107,735 
middle-aged males used self-reported BMI and alcohol use to assess liver-related 
mortality ascertained form record linkage, using ICD-10 codes K70-K76, demonstrating a 
U-shaped relationship between alcohol and mortality and BMI and mortality. Although 
there was evidence of synergy between low BMI and high alcohol, as in our study there 
was no evidence of interaction between high BMI and high alcohol use [38]. 
Our finding of increased risk in abstainers has precedent but is controversial. Previous 
studies have demonstrated the “J-shaped” relationship between alcohol and risk of 
mortality [39-42] or CLD [43, 44]. Some prospective studies have found that men but not 
women abstainers were at increased risk [9, 44], in contrast to the present study that 
provides a more comprehensive insight into the effects of weight and alcohol. Using raised 
aminotransferase levels to diagnose suspected NAFLD in men and women in NHANES 
the highest risk was seen in non-drinkers compared to modest drinkers [45], and in biopsy-
proven NAFLD, moderate drinkers had lower risk of steatohepatitis compared to non-
drinkers [46]. A prospective Danish study investigating risk of alcohol-related cirrhosis in 
over 30,000 participants found a dose-dependent increase in risk of cirrhosis with 
increasing alcohol in women, rather than a “J-shaped” relation which they observed in 
males [43]. 
We have confirmed this relationship with risk of CLD in our cohort, and also have 
demonstrated that the trend towards a “J-shape” relationship remains, irrespective of BMI 
group. 
The increased risk of alcoholic cirrhosis in abstainers compared to light drinkers may be 
due, in part, to this group containing previous drinkers who raise the overall risk in the 
abstainer group, rather than due to a true protective effect of alcohol in the light drinkers. 
One prospective study [35] demonstrated the loss of the “J-shaped” curve when lifetime 
abstainers were separated from current abstainers. In a small study of patients with 
biopsy-proven NAFLD, a comprehensive alcohol history was obtained and found to be 
higher than the original estimate at diagnosis in some patients, suggesting that some of 
these patients may have had alcohol-related liver disease rather than NAFLD [47].  
We found alcohol-related LREs in abstainers (although at less than half the rate seen in 
drinkers) which, although may partly be a function of miscoding, provides further evidence 
that this group comprises some ex-drinkers. 
Interaction between higher levels of alcohol consumption and NAFLD may result in greater 
risk of liver disease. A study measuring aminotransferase activity found that increased BMI 
potentiates the harmful effect of alcohol on the liver [48]. Increased aminotransferase 
levels were associated with higher alcohol consumption and BMI. In those with normal BMI 
there was no association between alcohol and raised aminotransferase levels, but in the 
overweight and obese groups, alcohol increased risk of elevated aminotransferases. A 
study of an older population also found risk of elevated aminotransferases with increased 
BMI and increased alcohol consumption (with lowest risk in abstainers), and a large 
synergistic effect in the obese group consuming more than three drinks/day [49]. This 
group also examined the risk of hepatocellular carcinoma in people with chronic hepatitis B, 
finding synergism between obesity and alcohol [50, 51]. 
Implications 
Our results suggest a substantial influence of both elevated BMI and alcohol on risk of 
CLD. Although no significant interaction between BMI and alcohol was seen and this lack 
of synergy is reassuring, the compelling risk in the overweight and obese groups adds to 
the evidence that rising BMI and increasing alcohol use are risk factors for liver disease 
among women. 
By considering the clinical consequences of liver disease beyond the diagnosis of cirrhosis 
we revealed a greater burden of disease than previously recognised. Currently much CLD 
goes undiagnosed until complications of cirrhosis result in serious morbidity and mortality. 
Earlier identification of those at risk could avert illness and reduce costs by targeted 
interventions. While the risks associated with heavy alcohol consumption are frequently 
publicised these data emphasise the importance of disseminating awareness of the risks 
of liver disease associated with BMI, particularly in light of the growing prevalence of 
overweight and obesity throughout the world [52]. Public health policy and health 
education and awareness campaigns should take these facts into account. 
Conclusion 
This study of post-menopausal women suggests that elevated BMI and high alcohol intake 
are independent risk factors for liver disease. Strategies for detecting liver disease and 
public health strategy should recognise the importance of BMI as well as alcohol when 
confronting the growing burden of liver disease. 	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Figure Legend 
Figure 1 
The composition of the final study cohort and its derivation from the UKCTOCS 
cohort 
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Figure S1 
Crude rates of first liver-related events (per 1000 person years) according to a) BMI category and b) 
alcohol consumption category over mean follow-up of 5.1 years 
 
The change in crude rates for first liver related events associated with increasing BMI and alcohol 
consumption are depicted. The rate of LRE rises with increasing BMI but follows a “J” or “U” shaped 
relationship with alcohol consumption in which abstinence is associated with a greater risk than moderate 
consumption (<1-15 units/week).  
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Table S1 
ICD-10 codes and death certificate text of first LREs 
The number of codes / death certificate text results is higher than the number of LREs 
(325) as some participants had more than one code when presenting with first LRE 
 
Source Code or text Number of 
participants 
(% of those 
with LRE) 
Hospital admission K70 15 (4.6) 
 K73 9 (2.8) 
 K74 45 (13.8) 
 K76 183 (56.3) 
 C22.0 7 (2.2) 
 I85 12 (3.7) 
 Z94.4 33 (10.2) 
Outpatient appointment K74 1 (0.3) 
 Z94.4 11 (3.4) 
Cancer registration C22.0 12 (3.7) 
Death certificate K70 6 (1.8) 
 K74 7 (2.2) 
 K76 10 (3.1) 
 C22.0 2 (0.6) 
 Mention of alcoholic liver 
disease 
8 (2.5) 
 Mention of non-alcoholic 
fatty liver disease 
8 (2.5) 	  
 
